|
Selected Publications
1. Lee DJ, Van Dyke GS, Kim J. Update on pathogenesis of acne. Curr Opin Pediatr, 15:405-410, 2003.
2. Arora T, Liu B, He H, Kim J, Murphy TL, Murphy KM, Modlin RL, Shuai K. Inhibition of Stat-4-mediated gene activation by PIASx. J Biol Chem 278:21327-21330, 2003.
3. Kim J, Ochoa MT, Krutzik S, Takeuchi O, Uematsu S, Legaspi A, Brightbill H, Holland D, Cunliffe WJ, Akira S, Sieling PA, Godowski PJ, Modlin RL. Activation of inflammatory cytokine responses in acne occurs through Toll-like receptor 2. J Immunol 169:1535-1541, 2002.
4. Grimes PE, Bhawan J, Kim J, Chiu M, Lask G. Laser resurfacing-induced hypopigmentation: histologic alterations and repigmentation with topical photochemotherapy. Dermatol Surg 27:515-520, 2001.
5. Kim J, Uyemura K, Van Dyke MK, Legaspi A, Presky DH, Rea TH, Shuai K, Modlin RL. A role for IL-12 receptor expression and signal transduction in host defense in leprosy. J Immunol 167:779-786, 2001.
6. Yamauchi PS, Bleharski JR, Uyemura K, Kim J, Sieling PA, Miller A, Brightbill H, Schlienger K, Rea TH, Modlin RL. A role for CD40-CD40 ligand interactions in the generation of type 1 cytokine responses in human leprosy. J Immunol 165:1506-1512, 2000.
7. Kim J, Beddingfield FC, Lask GP. Non-ablative facial resurfacing. Operative Techniques in Oculoplastic, Orbital, and Reconstructive Surgery 3:55-57, 2000.
8. Kim J, Sette A, Rodda S, Southwood S, Mehra V, Oliveros J, Sieling PA, Rea TH, Bloom BR, Modlin RL. Determinants of T-cell reactivity to the Mycobacterium leprae GroES homolog. J Immunol 159:335-343, 1997.
9. Kim J, Modlin RL, Moy RL, Dubinett S, McHugh T, Nickoloff BJ, Uyemura K. IL-10 production in cutaneous basal and squamous cell carcinomas: a mechanism for evading the local T Cell immune response. J Immunol 155: 2240-2247, 1995.
10. Ohmen JD, Hanifin JM, Nickoloff BJ, Rea TH, Wyzykowski R, Kim J, Jullien D, McHugh T, Nassif AS, Chan SC, Modlin RL. Overexpression of IL-10 in atopic dermatitis. J Immunol 154:1956-1963, 1995.
Research Interest:
Dr. Kim completed her medical degree, dermatology residency, and Mohs micrographic surgery fellowship at the University of California, Los Angeles. She also received her Ph.D. from UCLA in immunology and joined the faculty in 2000. Dr. Kim's clinical interests include skin cancer surgery, lasers, and aesthetic dermatology surgery. Her research focuses on the immunologic mechanisms of host responses in cutaneous inflammatory diseases and neoplasm, including acne and skin cancers. Dr. Kim conducts both basic and clinical research in dermatologic science. In particular, her interest is in translational medicine, bringing scientific results from the bench to the bedside.
Dr. Kim's basic science research projects are funded by the National Institutes of Health, the Dermatology Foundation, and the American Society for Dermatologic Surgery. Dr. Kim's laboratory currently focuses on two specific areas:
- Studying the mechanism of Toll-like receptor responses (innate immunity) in skin diseases.
- Determining genes that are important in the development and progression of skin cancers.
Dr. Kim is involved with clinical trials that focus on new dermatology therapies that are immune-based. Current active clinical trials open for patient enrollment include the following:
- A phase IIIb, multicenter study to evaluate the safety of 1.0 mg/kg subcutaneously administered Efalizumab in adults with moderate to severe plaque psoriasis, including those who are receiving concomitant antipsoriatic therapies or have recently transitioned from systemic therapies (Genentech sponsored trial).
|
